Table. Demographics, clinical features, treatments, and outcomes of the 3 COVID-19–associated MIS-C case-patients, South Korea, May–November 2020*.

Characteristics	Case 1	Case 2	Case 3
Age, y	11	11	14
Sex	Boy	Boy	Girl
Underlying disease	None	None	None
Clinical signs and symptoms
Initial symptoms	Fever, abdominal pain	Fever, abdominal pain, headache, nausea, vomiting	Fever, abdominal pain, diarrhea
Fever	Present	Present	Present
Conjunctival injection	Present	Present	Present
Mucosal change	Present	None	Present
Skin rash	Present	None	Present
Extremity changes	Present	None	Present
Lymphadenopathy	None	None	None
Gastrointestinal symptoms	Present	Present	Present
Hypotension	Present	Present	Present
Inflammatory markers (peak)
Leukocyte (neutrophil %), 103/μL	7.55 (87)	9.55 (82.8)	26.56 (93)
ESR, mm/h	NT	82	77
CRP, mg/L	18.95	10.36	>30
Fibrinogen, mg/dL	633	NT	NT
Procalcitonin, ng/mL	14.55	1.54	9.62
D-dimer, μg/mL	894	2.5	3.95
Ferritin, μg/mL	NT	2485	663
IL-6, pg/mL	NT	NT	2410
Abnormal imaging studies
Echocardiography	Coronary dilatation	Mitral regurgitation	Coronary dilatation, left ventricle dysfunction
Chest radiography or CT	Bilateral pleural effusion, pneumonic infiltration	Suspected pulmonary edema	Bilateral pulmonary edema, pleural effusion
Abdominal ultrasound or CT	Abdominal lymphadenopathy	Mesenteric lymphadenopathy	Hyperechoic liver, gallbladder hypertrophic edema, peripancreatic fluids, splenomegaly, scant pelvic ascites
Treatment
IVIg	Provided	Provided	Provided
ASA	Provided	Provided	Provided
Steroids	Not provided	Not provided	Provided
Immunomodulatory	Not provided	Not provided	Provided (Anakinra)
Inotropic agent	Provided	Not provided	Provided
ICU care	Provided	Not provided	Provided
Mechanical ventilator	Not provided	Not provided	Not provided
Outcome
Hospitalization, d	12 d	10 d	19 d
ICU admission, d	6 d	NA	7 d
Prognosis	Improved, discharged	Improved, discharged	Improved, discharged

*MIS-C clinical case definition is as follows: age <19 y, fever >38.0°C for >24 h, laboratory evidence of inflammation (i.e., elevation of ESR, CRP, fibrinogen, procalcitonin, d-dimer, ferritin, LDH, IL-6, neutrophilia, lymphopenia, hypoalbuminemia), multisystem involvement (>2 organ systems involved), severe illness requiring hospitalization, and no other plausible microbial cause of inflammation (i.e., bacterial sepsis, staphylococcal/streptococcal toxic shock syndromes, enteroviral myocarditis). Evidence of SARS-CoV-2 exposure history defined as positive SARS-CoV-2 by RT-PCR, positive serology (neutralizing antibody or anti-SARS-CoV-2 IgG), or exposure to individual with COVID-19 <4 weeks before onset of symptoms (epidemiologic linkage with individual or cluster). ASA, acetylsalicylic acid; COVID-19, coronavirus disease 2; CRP, c-reactive protein; CT, computed tomography; ESR, erythrocyte sedimentation rate; ICU, intensive care unit; IL-6, interleukin 6; IVIg, intravenous immunoglobulin; LDH, lactate dehydrogenase; MIS-C, multisystem inflammatory syndrome in children; NA, not applicable; NT, not tested; RT-PCR, reverse transcription PCR; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.